| Revision as of 19:30, 8 November 2005 editBluebot (talk | contribs)349,597 editsm Robot updating {{Journal reference issue}} with {{Journal reference}}← Previous edit | Revision as of 03:05, 21 December 2005 edit undoKerowyn (talk | contribs)Extended confirmed users10,072 editsNo edit summaryNext edit → | ||
| Line 7: | Line 7: | ||
| {{ |
{{neuroscience-stub}} | ||
Revision as of 03:05, 21 December 2005
First described by Moersch and Woltman at the Mayo Clinic in 1956, stiff person syndrome (SPS) is a rare neurologic disorder of unknown etiology. Those with the illness experience progressive, fluctuating tonic contractions of all muscles, particularly the axial musculature. Inability to walk and paralysis quickly ensues; death usually occurs six to twelve months after diagnosis.
Treatment is mostly palliative with muscle relaxants such as benzodiazepines, which lose their effectiveness as the illness progresses. Because many patients with SPS have circulating antibodies to glutamic acid decarboxylase, an autoimmune genesis to the disease has been postulated. In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend humane trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion.
References
Template:Journal reference PMID 13350379
 | This neuroscience article is a stub. You can help Misplaced Pages by expanding it. |